Project Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

2/3-Atomoxetine placebo and parent training in autism  

There have been relatively few randomized clinical trials of pharmacology for attention-deficit/hyperactivity (ADHD) in children with autism spectrum disorders (ASD). Atomoxetine (ATX) was approved by the FDA in January 2003 for treatment of ADHD, but only 4 studies of this drug have been conducted in children with ASD. Behavioral treatments, such as training parents in the use of behavioral interventions (PMT), are also standard treatments for ADHD in typically developing children. While PMT also has long been used in ASD, it has rarely been studied in combination with psychopharmacologic treatment in this population. This three-pronged, 10-week trial in children with ASD will compare atomoxetine vs. placebo, PMT vs. no-PMT, and combined ATX/PMT vs. PMT alone. This trial has the potential to provide answers regarding optimal treatment (both psychosocial and pharmacological) for a sizeable subgroup of children with ASD who experience symptoms of over activity and inattention. Project Status
ONGOING

2009

Funder National Institutes of Health
Fiscal Year Funding $358,106.00
Project Number 5R01MH079080-02
Principal Investigator Aman, Michael
Received ARRA Funding? No
Strategic Plan Question Question 4: Which Treatments And Interventions Will Help? (Interventions)
Strategic Plan Objective New! Yellow dot: Objective has some degree of funding, but less than the recommended amount. 4SF. Launch five randomized controlled trials of interventions including biological signatures and other measures to predict response, and monitor quality of life and functional outcomes, in each of the following groups:
  • Five trials in infants and toddlers by 2013. IACC Recommended Budget: $30,000,000 over 5 years.
  • Three randomized controlled trials of interventions for school-aged children and/or adolescents by 2013. IACC Recommended Budget: $18,000,000 over 5 years.
  • Three trials for adults by 2014. IACC Recommended Budget: $18,000,000 over 5 years.
Federal or Private? Federal
Institution The Ohio State University
State/Country Ohio
Web Link 1 2/3-Atomoxetine placebo and parent training in autism (External web link)
Web Link 2 No URL available.
Web Link 3 No URL available.
New! History/Related Projects 2/3-Atomoxetine placebo and parent training in autism | $361,873.00 | 2010 | 7R01MH079080-04
2/3-Atomoxetine placebo and parent training in autism | $343,820.00 | 2008 | R01MH079080-01A2